valsartan has been researched along with Atherosclerosis in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M; Zupan, J | 1 |
| Chai, M; Dong, Z; Ji, Q; Lin, Y; Liu, Y; Lu, Q; Meng, K; Wu, B; Yu, K; Zeng, Q; Zhang, J; Zhou, Y | 1 |
| Fan, F; Li, S; Nie, W; Yan, H; Zhu, J; Zhu, W | 1 |
| Higashi, Y; Hikita, K; Honda, M; Kawamoto, B; Muraoka, K; Saito, M; Sejima, T; Shimizu, S; Shimizu, T; Takenaka, A | 1 |
| Chen, X; Deng, Y; Ding, D; Hu, X; Liao, Y; Pan, Y; Qiu, Z; Song, X; Wang, M; Wang, S; Wu, H; Yang, S; Zhang, H; Zhou, Y; Zhou, Z | 1 |
| Alkhoder, A; Binongo, JN; Dhawan, SS; Jones, DP; Oshinski, JN; Quyyumi, AA; Ramadan, R | 1 |
| He, S; Shi, W; Wang, L; Wang, X; Zhao, Y | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kitabata, H; Kuroi, A; Mochizuki, S; Muragaki, Y; Takarada, S; Tanimoto, T; Tsujioka, H; Yoshida, K | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, A; Tsujioka, H; Yoshida, K | 1 |
| Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH | 1 |
| Hawkins, NM; Huang, Z; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Pieper, KS; Solomon, SD; Swedberg, K; Velazquez, EJ | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Senba, I; Tomono, Y | 1 |
| Fu, L; Gao, Q; Li, Y; Ma, D | 1 |
| Janić, M; Jug, B; Lunder, M; Sabovič, M | 1 |
| Aono, J; Higaki, J; Horiuchi, M; Inoue, K; Iwai, M; Nagai, T; Nishimura, K; Ogimoto, A; Okayama, H; Suzuki, J | 1 |
| Chen, R; Horiuchi, M; Ide, A; Iwai, M; Li, Z; Min, LJ; Mogi, M; Okumura, M; Shiuchi, T; Suzuki, J; Tsuda, M | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H | 1 |
| de Gasparo, M | 1 |
| Azuma, K; Hirose, T; Ikeda, F; Kawamori, R; Mita, T; Ogihara, T; Otsuka, A; Tanaka, Y; Toyofuku, Y; Watada, H | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Mogi, M; Tomono, Y | 1 |
1 review(s) available for valsartan and Atherosclerosis
| Article | Year |
|---|---|
New basic science initiatives with the angiotensin II receptor blocker valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atherosclerosis; Cell Proliferation; Endothelium, Vascular; Humans; Inflammation; Tetrazoles; Valine; Valsartan; Vasoconstriction; Ventricular Remodeling | 2000 |
2 trial(s) available for valsartan and Atherosclerosis
| Article | Year |
|---|---|
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Cause of Death; Confidence Intervals; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Prognosis; Proportional Hazards Models; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
Topics: Adult; Aging; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Blood Flow Velocity; Brachial Artery; Carotid Arteries; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pulsatile Flow; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2012 |
18 other study(ies) available for valsartan and Atherosclerosis
| Article | Year |
|---|---|
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, Atherogenic; Drug Therapy, Combination; Female; Guinea Pigs; Heptanoic Acids; Interleukin-1beta; Male; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Protective Agents; Pyrroles; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Monoclonal; Apolipoproteins E; Atherosclerosis; Blood Pressure; Body Weight; Disease Models, Animal; Inflammation; Interleukin-5; Lipids; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; T-Lymphocyte Subsets; Th2 Cells; Valsartan | 2015 |
Angiotensin II Promotes Atherogenesis through upregulating the Expression of Connexin 43 in Dendritic Cells.
Topics: Angiotensin II; Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; CD40 Antigens; Cells, Cultured; Connexin 43; Dendritic Cells; Immunohistochemistry; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Smooth Muscle; Up-Regulation; Valsartan | 2015 |
Vesicovascular reflexes in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Blood Vessels; Epinephrine; Hypertension; Male; Myocardium; Nifedipine; Norepinephrine; Pulse Wave Analysis; Rats; Rats, Inbred SHR; Rats, Wistar; Reflex; Valsartan; Vasodilator Agents | 2016 |
ATRQβ-001 vaccine prevents atherosclerosis in apolipoprotein E-null mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Neutralizing; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Chemokine CCL2; Coronary Vessels; Endothelial Cells; Humans; Macrophages; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Scavenger Receptors, Class E; Vaccines; Valsartan; Vasoconstrictor Agents | 2016 |
Effect of Angiotensin II Type I Receptor Blockade with Valsartan on Carotid Artery Atherosclerosis: A Double Blind Randomized Clinical Trial Comparing Valsartan and Placebo (EFFERVESCENT).
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Treatment Outcome; Valsartan; Young Adult | 2016 |
Nitric oxide synthesis-promoting effects of valsartan in human umbilical vein endothelial cells via the Akt/adenosine monophosphate-activated protein kinase/endothelial nitric oxide synthase pathway.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Antihypertensive Agents; Atherosclerosis; Chromones; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Human Umbilical Vein Endothelial Cells; Humans; Morpholines; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Valsartan | 2017 |
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Topics: Acetylcholine; Amides; Animals; Antihypertensive Agents; Atherosclerosis; Biopterins; Blood Pressure; Drug Therapy, Combination; Endothelium, Vascular; Fumarates; Heart Rate; HSP90 Heat-Shock Proteins; Hyperlipidemias; Inflammation Mediators; Lipids; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rabbits; Renin; Tetrazoles; Tyrosine; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2008 |
Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biological Availability; Drug Therapy, Combination; Echocardiography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Nitric Oxide; Quinolines; Rabbits; Reactive Oxygen Species; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Coronary Artery Disease; Disease Models, Animal; Endothelium, Vascular; Inflammation; Lipids; Male; Rabbits; Risk; Simvastatin; Stress, Mechanical; Tetrazoles; Valine; Valsartan | 2009 |
AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Count; Cell Differentiation; Cholesterol, Dietary; Insulin Receptor Substrate Proteins; Male; Mice; Mice, Knockout; NADPH Oxidases; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan alleviates atherosclerotic lesions in pulmonary arteries of rabbits via an endothelium-dependent mechanism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Endothelium, Vascular; Lipids; Male; Nitric Oxide; Pulmonary Artery; Rabbits; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vasodilation | 2010 |
Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Carotid Artery Diseases; Carotid Artery, Common; CD36 Antigens; Disease Models, Animal; Disease Progression; Focal Adhesion Kinase 1; Gene Deletion; JNK Mitogen-Activated Protein Kinases; Lipids; Lipoproteins, LDL; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Rupture, Spontaneous; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |
Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
Topics: Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Gene Deletion; Imidazoles; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Atherosclerosis; Blood Pressure; Cell Adhesion; Deoxyguanosine; Endothelial Cells; Hydralazine; Hypertension; Male; Monocytes; Rats; Rats, Inbred SHR; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan | 2007 |
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
Topics: Adipocytes, White; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Differentiation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gene Deletion; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2008 |